ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Tuesday, November 14, 2023

9:00AM-11:00AM: Abstract Number: 2147

Safety and Effectiveness in Cycling Between Non-Selective and Selective JAKi in a Multi-Center Registry of Rheumatoid Arthritis in the Middle East

(2141–2176) RA – Treatments Poster III

9:00AM-11:00AM: Abstract Number: 2162

Safety and Efficacy of Filgotinib: An Update from the DARWIN 3 Phase 2 Long-term Extension with a Maximum of 8.2 Years of Exposure

(2141–2176) RA – Treatments Poster III

9:00AM-11:00AM: Abstract Number: 2337

Safety and Tolerability of NIM-1324, an Oral, Once-daily LANCL2 Agonist, in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study in Normal Healthy Volunteers

(2326–2351) SLE – Treatment Poster III

9:00AM-11:00AM: Abstract Number: 2047

Safety of Baricitinib for COVID-19 Related Hyperinflammation in Pediatric Patients: A Large Tertiary Care Center Experience

(2039–2060) Pediatric Rheumatology – Clinical Poster III: Potpourri

9:00AM-11:00AM: Abstract Number: 2190

Saliclick: A Novel Technology for Minimal Invasive Salivary Gland Biopsy in Suspected Sjögren’s Syndrome

(2177–2194) Sjögren’s Syndrome – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 2180

Salivary and Plasma Mitochondrial Double-strand RNAs as a Diagnostic Biomarker for Sjӧgren Syndrome

(2177–2194) Sjögren’s Syndrome – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 1915

Scleritis and Development of Autoimmune Disease: A Case Series

(1913–1944) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

9:00AM-11:00AM: Abstract Number: 2288

Scoping Literature Review and Focus Groups Interviews to Identify Candidate Domains for the SLE OMERACT Core Domain Set

(2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 2129

SCORE and SCORE2 Comparison in Cardiovascular Risk Estimation in Rheumatoid Arthritis Patients: A Cross-sectional Study Including Carotid Ultrasound

(2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 2009

Screening and Treatment of Low Bone Mineral Density in Allogeneic Hematopoietic Cell Transplant Patients

(1996–2018) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2051

Screening Multisystem Inflammatory Syndrome in Children: Accuracy of SickKids Screening Pathway Compared to ACR Algorithm

(2039–2060) Pediatric Rheumatology – Clinical Poster III: Potpourri

9:00AM-11:00AM: Abstract Number: 2005

Secondary Prevention of Osteoporosis in Hip Fracture Care for Elderly Patients. Clinical and Functional Profile of Users

(1996–2018) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2181

Secretagogue Effect of PDE4 Inhibitor Apremilast on Human Salivary Gland Organoids Obtained from Primary Sjögren’s Syndrome Patients

(2177–2194) Sjögren’s Syndrome – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 1907

Selection of a Candidate Instrument to Assess Flare in Osteoarthritis with Content Matching with Endorsed Domains

(1895–1912) Measures & Measurement of Healthcare Quality Poster II

9:00AM-11:00AM: Abstract Number: 2349

Selection of the Dose for Subcutaneous Administration to Non-Japanese Subjects and Intravenous Administration to Japanese Subjects in the First-in-Human Study of DS-7011a, an Anti-TLR7 Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus

(2326–2351) SLE – Treatment Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].